Skip to main content
Premium Trial:

Request an Annual Quote

Egeen, Prediction Sciences Kick-Off Antidepressant Pharmacogenomics Study: Jul 24, 2002 (rev. 2)

NEW YORK, July 24 - Egeen International is collaborating with Prediction Sciences on a gene and SNP-linked pharmacogenomics study for the antidepressant Celexa, the companies said today.

 

The study is the first step in an attempt to create a gene- and SNP-based diagnostics panel designed to help predict an individual's response to a number of different antidepressants, said Cornelius Diamond, director of the pharmacogenomics group at San Diego-based Prediction Sciences.

 

Egeen, headquartered in Redwood City, Calif., will enroll patients in the former Eastern Bloc nation of Estonia who are now taking or have taken in the past Celexa, made by Forest Laboratories. To evaluate the genomic profile of responders and nonresponders, the company will genotype the patients and, taking advantage of its relationship with the Estonian government, get access to the country's state-sponsored gene bank, said Kalev Kask, CEO of Egeen. He said the study would take 24 months.

 

Kask called the collaboration an "early stage revenue-generating service deal" for Egeen, which he said will win milestone payments and royalties from Prediction Sciences for sales of a diagnostic product.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.